scholarly journals Early Detection of Neuroendocrine Prostate Cancer as Lineage Plasticity in Recurrent Prostate Cancer After Radiation and Androgen Deprivation Therapy: A Case Report

2020 ◽  
Author(s):  
Takahiro Komori ◽  
Takeo Kosaka ◽  
Keitaro Watanabe ◽  
Yota Yasumizu ◽  
Shuji Mikami ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Androgen Deprivation Therapy ◽  
Cancer Detection ◽  
External Beam Radiotherapy ◽  
Specific Antigen ◽  
Androgen Deprivation ◽  
Resonance Imaging ◽  
Prostate Cancer Detection ◽  
Neuroendocrine Prostate Cancer ◽  
Salvage Androgen Deprivation Therapy

Abstract Background: Neuroendocrine prostate cancer is one of the most aggressive prostate cancers, with severely poor prognosis. However, its detection is difficult because no useful marker has been found so far. In addition, serum prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA), and PSMA positron emission tomography/computed tomography don’t help in neuroendocrine prostate cancer. However, its early detection is necessary because its prognosis is poor.Case presentation: We described three cases of early neuroendocrine prostate cancer detection after initial external beam radiotherapy followed by salvage androgen deprivation therapy (ADT). We used Magnetic Resonance Imaging for three ADT-resistant patients, and it detected neuroendocrine prostate cancer in all three, although the PSA level was <2 ng/mL.Conclusions: Magnetic resonance imaging might be a better modality for neuroendocrine prostate cancer detection despite low serum prostate-specific-antigen levels.. Our findings in these three cases will help establish better criteria or better follow-up for patients administered salvage androgen deprivation therapy for biochemical recurrence of prostate cancer after external beam radiotherapy.

Early versus delayed initiation of salvage androgen deprivation therapy and the risk of prostate cancer-specific mortality.

2018 ◽  
Vol 36 (6_suppl) ◽  
pp. 189-189
Author(s):  
Brandon Arvin Virgil Mahal ◽  
Ming-Hui Chen ◽  
Andrew A. Renshaw ◽  
Philip W. Kantoff ◽  
Anthony Victor D'Amico
Keyword(s):  
Prostate Cancer ◽  
Androgen Deprivation Therapy ◽  
Specific Antigen ◽  
Androgen Deprivation ◽  
Early Initiation ◽  
Study Cohort ◽  
Increased Risk ◽  
Specific Mortality ◽  
Salvage Androgen Deprivation Therapy

189 Background: We sought to ascertain whether there is an association between prostate cancer (PC)-specific mortality (PCSM) and salvage androgen deprivation therapy (ADT) timing amongst men with short versus long prostate-specific antigen doubling times (PSA-DT)s. Methods: The study cohort was selected from 206 men with localized unfavorable-risk PC who were randomized to radiation therapy (RT) or RT plus 6 months of ADT between 1995 and 2001. Fifty-four men who received salvage ADT for PSA failure after a median follow up of 18.72 years following randomization defined the study cohort. Fine-Gray competing risks regression analyzed whether the timing of salvage ADT was associated with an increased risk of PCSM after adjusting for age, comorbidity, known PC prognostic factors, and previously identified interactions. Results: After a median follow-up of 5.68 years (IQR 3.05 - 9.56) following salvage ADT 49 of the 54 men (91%) died, 27 from PC (54% of deaths). Increasing PSA-DT as a continuous covariate was associated with a decreasing risk of PCSM (adjusted hazard ratio [AHR] 0.33, 95% CI 0.13, 0.82; P=0.02). Amongst men with a long PSA-DT (≥6 months), initiating salvage ADT later (PSA>12ng/mL, upper quartile) versus earlier was associated with an increased risk of PCSM (AHR 8.84, 95% CI 1.99-39.27; P=0.004); whereas for men with a short (<6 months) PSA-DT (AHR 1.16, 95% CI 0.38-3.54; P=0.79) this was not true. Conclusions: Early initiation of salvage ADT for post-RT PSA recurrence in men with a PSA-DT of 6 months or more may reduce the risk of PCSM, arguing against the unproven assumption that patients with a short PSA-DT are those most likely to benefit from early initiation of salvage ADT. Clinical trial information: NCT00116220.

The Role of Chromogranin A (CgA) in Monitoring Patients with Prostate Cancer Under Androgen Deprivation Therapy: Comparison with Prostatic Specific Antigen (PSA)

2008 ◽  
Vol 1 (2) ◽  
pp. 115-119
Author(s):  
Athanasios Bantis ◽  
Petros Sountoulides ◽  
Athanasios Zissimopoulos ◽  
Christos Kalaitzis ◽  
Stilianos Giannakopoulos ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Androgen Deprivation Therapy ◽  
Chromogranin A ◽  
Specific Antigen ◽  
Androgen Deprivation ◽  
Prostatic Specific Antigen

scholarly journals Impact of Androgen Deprivation Therapy Associated to Conformal Radiotherapy in the Treatment of D’Amico Intermediate-/High-Risk Prostate Cancer in Older Patients

Cancers ◽  
2020 ◽  
Vol 13 (1) ◽  
pp. 75
Author(s):  
Anne-Laure Couderc ◽  
Emanuel Nicolas ◽  
Romain Boissier ◽  
Mohammed Boucekine ◽  
Cyrille Bastide ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Androgen Deprivation Therapy ◽  
Older Patients ◽  
External Beam Radiotherapy ◽  
Total Duration ◽  
Androgen Deprivation ◽  
Free Survival ◽  
Cancer Group ◽  
Tertiary Center

Purpose/objective: The association of 3D Conformal External Beam Radiotherapy (3D-CEBRT) with adjuvant Androgen Deprivation Therapy (ADT) proved to treat patients with intermediate- and high-risk localized prostate cancer (IR and HR). However, older patients were underrepresented in literature. We aimed to report the oncological results and morbidity 3D-CEBRT +ADT in ≥80 years patients. Material and Methods: From June 1998 to July 2017, 101 patients ≥80 years were included in a tertiary center. The median age was 82 years. ADT was initiated 3 months prior 3D-CEBRT in all patients, with a total duration of 6 months for IR prostate cancer (group A; n = 41) and 15 months for HR prostate cancer (group B; n = 60). Endpoints included overall survival (OS), metastasis-free survival (DMFS), biochemical recurrence-free survival (BRFS) and toxicity. Results: Five years-OS was 95% and 86.7% in groups A and B, respectively. Cardiovascular events occurred in 22.8% of ≥80 years patients with no impact on OS. In the multivariate analysis, age <82 years, Karnofsky index and normalization of testosterone levels were significantly associated with better OS. Conclusion: Age ≥80 years should not be a limitation for the treatment of IR and HR prostate cancer patients with 3D-CEBRT and ADT, but cardiovascular monitoring and prevention are mandatory.

Sign in / Sign up

Export Citation Format

Share Document